United Natural Foods (UNFI) - FREE Research Report

Heffernan James P who is Director at United Natural Foods sold 1,064 shares at $67.45 on Oct. 15, 2013. Following this transaction, the Director owned 800 shares meaning that the stake was reduced by 57.08% with the 1,064 share transaction.

The shares most recently traded at $66.18, down $1.27, or 1.92% since the insider transaction. Historical insider transactions for United Natural Foods go as follows:

  • 4-Week # shares sold: 35,131
  • 12-Week # shares sold: 42,156
  • 24-Week # shares sold: 59,571

The average volume for United Natural Foods has been 267,400 shares per day over the past 30 days. United Natural Foods has a market cap of $3.3 billion and is part of the services sector and wholesale industry. Shares are up 25.71% year to date as of the close of trading on Friday.

United Natural Foods, Inc., together with its subsidiaries, distributes and retails natural, organic, and specialty foods, as well as non-food products primarily in the United States and Canada. The company has a P/E ratio of 30.6. Currently there are 5 analysts that rate United Natural Foods a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UNFI - FREE

TheStreet Quant Ratings rates United Natural Foods as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full United Natural Foods Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal